BioCryst Pharmaceuticals Rating Lowered to Neutral at Zacks

Home › BioCryst Pharmaceuticals Rating Lowered to Neutral at Zacks

They currently have a $2.00 price target on the stock. A number of other analysts have also recently weighed in on BCRX.

06.10	Atlantic Tropical Weather Outlook
06.10	Tropical Storm Milton Graphics
06.10	Tropical Storm Milton Public Advisory Number 3A
06.10	Summary for Tropical Storm Milton (AT4/AL142024)
06.10	Eastern North Pacific Tropical Weather Outlook
06.10	Hurricane Leslie Graphics
06.10	Hurricane Kirk Graphics
06.10	Hurricane Leslie Forecast Discussion Number 15
More »

je.st